Growth & profitability
- Revenue has grown 153.5% per year over the past 5 years.
Financial health
- The company is unprofitable; at its current free-cash-flow burn it has roughly 1.4 years of cash runway.
ASMB Financials Assembly Biosciences, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $72M | -$6M | 0.0% | -16.8% | -$41M | — | $58M |
| 2024 | $29M | -$40M | 0.0% | -159.3% | -$51M | — | $38M |
| 2023 | — | -$61M | — | — | $22M | — | $20M |
| 2022 | — | -$93M | — | — | -$85M | — | $52M |
| 2021 | — | -$130M | — | — | -$96M | — | $46M |
| 2020 | — | -$62M | — | — | -$63M | — | $59M |
| 2019 | — | -$98M | — | — | -$86M | — | $47M |
| 2018 | — | -$91M | — | — | -$65M | — | $41M |
| 2017 | — | -$43M | — | — | $995000 | — | $82M |
| 2016 | — | -$44M | — | — | -$35M | — | $29M |
| 2015 | — | -$28M | — | — | -$19M | — | $27M |
| 2014 | — | -$24M | — | — | -$15M | — | $29M |
| 2014 | — | -$116M | — | — | -$85M | — | $24M |
| 2013 | — | -$19M | — | — | -$18M | — | $27M |
| 2013 | — | -$106M | — | — | -$74M | — | $32M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $8M | -$9M | 0.0% | -138.4% | -$22M | — | $31M |
| Dec '25 | — | $22M | — | — | $14M | — | $58M |
| Sep '25 | $11M | -$9M | 0.0% | -100.9% | -$15M | — | $23M |
| Jun '25 | $10M | -$10M | 0.0% | -115.2% | -$17M | — | $24M |
| Mar '25 | $9M | -$9M | 0.0% | -105.5% | -$23M | — | $23M |
| Dec '24 | $7M | -$10M | 0.0% | -156.7% | -$407000 | — | $38M |
| Sep '24 | $7M | -$10M | 0.0% | -160.1% | -$15M | — | $28M |
| Jun '24 | $9M | -$11M | 0.0% | -143.0% | -$17M | — | $19M |
| Mar '24 | $6M | -$9M | 0.0% | -185.5% | -$18M | — | $19M |
| Dec '23 | $7M | -$11M | 0.0% | -175.2% | $74M | — | $20M |
| Sep '23 | $0 | -$14M | — | — | -$14M | — | $27M |
| Jun '23 | $0 | -$17M | — | — | -$14M | — | $22M |
| Mar '23 | $0 | -$19M | — | — | -$23M | — | $43M |
| Dec '22 | — | -$22M | — | — | -$19M | — | $52M |
| Sep '22 | — | -$23M | — | — | -$20M | — | $55M |
| Jun '22 | — | -$24M | — | — | -$18M | — | $43M |
| Mar '22 | — | -$23M | — | — | -$28M | — | $51M |
| Dec '21 | $0 | -$60M | — | — | -$19M | — | $46M |
| Sep '21 | $6M | -$19M | 0.0% | -301.8% | -$19M | — | $71M |
| Jun '21 | — | -$24M | — | — | -$22M | — | $60M |
Valuation over time
How the market has priced ASMB against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 8.8× (Dec '24) to 5.3× (Jun '26).
P/S
Frequently asked questions
Is ASMB growing its revenue and profit?
Over the past 5 years, Assembly Biosciences, Inc.'s revenue has grown 153.5% per year. These are computed facts, not advice.
How much debt does ASMB have?
As of FY2025, Assembly Biosciences, Inc. reported — of total debt against $58M of cash.
What is ASMB's profit margin?
In FY2025, gross margin was —, operating margin -16.8%, and net margin -8.5%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.